-

05:47:13 AM

AKTX Stock News

AKTX - Akari Therapeutics Plc

05/19/22 4:05 PM

Nasdaq : AKTX

covid-19

Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, presented results from the CASCADE and CORONET studies in patients with COVID-19

RHEA-AI

neutral

05/16/22 6:00 AM

Nasdaq : AKTX

earnings

Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress

Clinical trial sites open and enrolling patients in FDA and EMA registration-directed Phase III Part A study of nomacopan in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) FDA and EMA registration-directed Phase III Part A study of nomacopan in bullous

RHEA-AI

neutral

05/11/22 7:00 AM

Nasdaq : AKTX

conferencescovid-19

Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that two posters will be presented at the American Thoracic Society

RHEA-AI

neutral

05/10/22 7:00 AM

Nasdaq : AKTX

Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology

Patients received subcutaneous nomacopan (30 mg once daily) with lesional mometasone from Day 1 to 21 of treatment and nomacopan only from Day 21 to Day 42 Seven of nine patients responded to nomacopan with three, regarded as complete responders, showing >80% reduction in BPDAI (BP disease activity

RHEA-AI

neutral

05/09/22 7:00 AM

Nasdaq : AKTX

clinical trial

Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC)

Preclinical data show investigational intravitreal long-acting PASylated-nomacopan (PAS-nomacopan) effective in inhibiting choroidal neovascularization (CNV), which is a risk related to certain complement inhibitors that otherwise appear to be effective in the treatment of GA 1, 2 Initial

RHEA-AI

neutral

03/21/22 8:00 AM

Nasdaq : AKTX

conferences

Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,

RHEA-AI

neutral

03/09/22 7:30 AM

Nasdaq : AKTX

Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and

RHEA-AI

neutral

03/08/22 11:45 AM

Nasdaq : AKTX

offering

Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering

Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are

RHEA-AI

neutral

03/02/22 7:00 AM

Nasdaq : AKTX

management

Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer

Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company

RHEA-AI

neutral

02/28/22 9:12 AM

Nasdaq : AKTX

Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma

Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of trauma A follow-on program relevant to both military and civilian trauma is planned as the next steps toward a clinical study Project was funded by the DoD U.S. Army

RHEA-AI

neutral

AKTX Data

IndustryPharmaceutical Preparation Manufacturing
Websiteakaritx.com
CeoDavid Solomon
Security nameAkari Therapeutics Plc - ADR
Issue typead
SectorManufacturing
Sic code2834
Employees2020
Tags
- Health Technology
- Pharmaceuticals: Major
- Manufacturing
- Medicinal and Botanical Manufacturing
Address24 W 40th St Fl 8
StateNew York
CityNew York
Zip10018-1028
CountryUS
Phone16463500702

About Akari Therapeutics Plc

Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.